StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK)

Investment analysts at StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report released on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

Shares of NASDAQ EVOK opened at $4.22 on Tuesday. The stock has a market capitalization of $3.46 million, a price-to-earnings ratio of -2.31 and a beta of 0.38. Evoke Pharma has a 12 month low of $3.54 and a 12 month high of $18.60. The firm’s 50 day simple moving average is $5.27 and its 200-day simple moving average is $5.99.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). The firm had revenue of $2.55 million for the quarter. Evoke Pharma had a negative return on equity of 964.25% and a negative net margin of 86.74%.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.